Market overview

The Prenatal Genetic Testing Market is entering a period of sustained expansion as healthcare providers, expecting parents, and fertility specialists increasingly adopt genetic screening for early identification of fetal chromosomal and inherited abnormalities. According to Maximize Market Research, the market was valued at USD 12.81 billion in 2025 and is projected to reach approximately USD 20.57 billion by 2032, expanding at a 6.1% CAGR between 2026 and 2032. Prenatal genetic testing helps identify risks associated with conditions such as Down syndrome, Edwards syndrome, Patau syndrome, and inherited genetic disorders. The increasing age of first-time mothers, greater awareness of genetic conditions, growth in assisted reproductive technologies, and improvements in next-generation sequencing are among the major factors supporting market growth. The transition from invasive procedures toward safer cell-free DNA-based screening is creating significant opportunities for laboratories and technology providers.

Market Estimation, Growth Drivers and Opportunities

The market's growth is strongly connected to the rising prevalence of pregnancies among women of advanced maternal age. Pregnancy after the age of 35 is associated with increased risks of chromosomal abnormalities, encouraging physicians to recommend appropriate prenatal screening and diagnostic options. At the same time, growing awareness among expecting parents is increasing demand for early and reliable information about fetal health. Technological progress in non-invasive prenatal testing (NIPT) is another major opportunity. NIPT analyzes fetal cell-free DNA circulating in maternal blood and can reduce reliance on invasive procedures such as amniocentesis and chorionic villus sampling. Maximize Market Research identifies NGS, qPCR, digital PCR, improved amplification technologies, automated workflows, AI-assisted analysis, and expanded testing for rare chromosomal abnormalities and single-gene disorders as important future opportunities.

U.S. Market Trends and Investment in 2025

The United States remained a leading market because of its advanced healthcare infrastructure, high adoption of genetic testing, established laboratory networks, and increasing use of NIPT. In 2025, innovation focused increasingly on expanding testing beyond conventional aneuploidy screening. Natera launched Fetal Focus in August 2025, a non-invasive prenatal test designed to screen for inherited single-gene conditions when paternal testing is unavailable. The initial test covered five genes, including CFTR, SMN1, HBA1, HBA2, and HBB, with development supported by the prospective EXPAND clinical trial. In October 2025, Natera announced an expansion of Fetal Focus to 20 genes, demonstrating the industry's movement toward broader single-gene prenatal screening. Quest Diagnostics also expanded its QNatal Advanced portfolio in 2025 with additional testing configurations covering common trisomies, sex chromosome abnormalities and selected microdeletions. Labcorp further highlighted advances in cfDNA-based NIPT and prenatal genetic screening during its April 2025 clinical education initiative.

Request To Free Sample of This Strategic Report ➤ https://www.maximizemarketresearch.com/request-sample/90933/ 

Prenatal Genetic Testing Market – Segmentation

• By Tests

  • Screening Tests

  • Diagnostic Tests

  • Carrier Screening

• By Technology

  • Non-Invasive Prenatal Testing (NIPT)

  • Next-Generation Sequencing (NGS)

  • Polymerase Chain Reaction (PCR)

  • Microarray

  • Other Technologies

• By End User

  • Hospitals

  • Diagnostic Laboratories

  • Maternity & Specialty Clinics

  • Research Institutes

  • Other End Users

• By Region

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Competitive Analysis

Natera Inc. is a major participant in the market, with its Panorama NIPT and Horizon carrier screening forming a significant part of its women's health portfolio. In 2025, the company strengthened its position through the launch and expansion of Fetal Focus single-gene NIPT. Natera also continued its EXPAND prospective clinical trial, which enrolled more than 1,600 patients by October 2025.

Illumina Inc. remains a key technology provider through its sequencing platforms and reproductive-health solutions. Its NIPT technology supports analysis of cell-free DNA for fetal chromosomal abnormalities, while continued development of scalable sequencing technologies can improve testing capacity and enable broader genomic applications.

Thermo Fisher Scientific Inc. contributes through NGS and microarray technologies used in reproductive health, prenatal analysis, and follow-up investigations. Its reproductive-health portfolio supports applications including preimplantation genetic testing, carrier screening, and prenatal analysis, with technological advances helping laboratories identify genetic abnormalities with greater resolution.

Eurofins Scientific has established capabilities in NIPT and prenatal diagnostics through its PrenatalSAFE and clinical genetics businesses. Its 2025 materials emphasize non-invasive analysis of fetal genetic material from maternal blood. Eurofins also has a significant NIPT presence in Japan, supported by NGS technologies and accredited laboratory infrastructure.

BGI Genomics Co., Ltd. is another important participant, particularly in Asia. Its NIFTY prenatal testing program uses high-throughput sequencing and bioinformatics to detect common fetal chromosomal abnormalities. BGI reported millions of NIFTY prenatal tests globally, while its 2025 research on previously overlooked cell-free DNA signals demonstrated potential applications for prenatal care and other genomic fields.

Request To Free Sample of This Strategic Report ➤ https://www.maximizemarketresearch.com/request-sample/90933/ 

Regional Analysis

United States: The U.S. is the principal contributor to North America's leadership, supported by sophisticated diagnostic laboratories, widespread NIPT adoption, reproductive medicine infrastructure, and increasing availability of advanced genetic screening. Insurance coverage, genetic counseling, and the presence of major market participants further support demand. Maximize Market Research identifies North America as the largest regional market in 2025.

China: China represents the largest prenatal genetic testing market within Asia Pacific. Rising healthcare expenditure, expanding healthcare infrastructure, increasing awareness of inherited disorders, and growing adoption of genomic technologies are supporting demand. BGI's NIFTY testing ecosystem further demonstrates the country's substantial testing capabilities.

Japan: Japan is an important advanced market for prenatal genetic testing, supported by sophisticated healthcare services and structured approaches to NIPT implementation. Eurofins identifies Japan as a major NIPT market for its clinical genetics operations, while Japan's prenatal testing framework emphasizes certified facilities and appropriate information and counseling.

Key Players

• Illumina, Inc.

• Thermo Fisher Scientific Inc.

• Natera Inc.

• Eurofins Scientific

• BGI Genomics Co., Ltd.

• F. Hoffmann-La Roche Ltd.

• Laboratory Corporation of America Holdings

• Quest Diagnostics Incorporated

• Myriad Genetics, Inc.

• Agilent Technologies Inc.

Conclusion

The Prenatal Genetic Testing Market is positioned for steady long-term growth as genetic screening becomes increasingly integrated into routine prenatal care. The combination of advanced maternal age, rising awareness, NIPT adoption, NGS innovation, expanded carrier screening, AI-enabled genomic analysis, and growth in single-gene testing will remain central to market expansion.

 The strongest future opportunity lies in making highly accurate genomic testing more accessible while expanding screening to rare and inherited conditions without increasing procedural risks. Natera's 2025 Fetal Focus expansion illustrates how the industry is moving beyond traditional trisomy screening toward more comprehensive fetal genetic assessment. At the same time, continued clinical validation, appropriate genetic counseling, privacy safeguards, and harmonized regulatory standards will be essential for responsible market development. Overall, the combination of technological innovation and broader access to prenatal genomic services should create attractive opportunities for diagnostic laboratories, sequencing companies, hospitals, fertility centers, and healthcare technology providers through 2032.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

Contact Us

Maximize Market Research Pvt. Ltd.
2nd Floor, Navale IT Park Phase 3
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India
Phone: +91 9607365656
Email: sales@maximizemarketresearch.com